C4 Therapeutics Inc
NASDAQ:CCCC

Watchlist Manager
C4 Therapeutics Inc Logo
C4 Therapeutics Inc
NASDAQ:CCCC
Watchlist
Price: 2.08 USD 2.97% Market Closed
Market Cap: 201.6m USD

Operating Margin
C4 Therapeutics Inc

-395.4%
Current
-475%
Average
-4.2%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-395.4%
=
Operating Profit
-119.1m
/
Revenue
30.1m

Operating Margin Across Competitors

No Stocks Found

C4 Therapeutics Inc
Glance View

Market Cap
201.6m USD
Industry
Biotechnology

C4 Therapeutics, Inc. engages in the development of targeted protein degradation science to develop a new generation of small molecule medicines used for treating diseases. The company is headquartered in Watertown, Massachusetts and currently employs 121 full-time employees. The company went IPO on 2020-10-02. The firm is focused on harnessing the body’s natural regulation of protein levels to develop therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer, neurodegenerative conditions and other diseases. The firm provides technology platform, Target ORiented ProtEin Degrader Optimizer (TORPEDO), to synthesize a new class of small molecule protein degraders that are designed to destroy disease-causing proteins, including targets previously considered to be undruggable. The Company’s lead product candidates, CFT7455, is an orally bioavailable degrader targeting IKZF1/3 for multiple myeloma (MM), peripheral T-cell lymphoma (PTCL), and mantle cell lymphoma (MCL). The firm is also developing CFT8634, an orally bioavailable degrader of a protein target called bromodomain containing 9 (BRD9), for synovial sarcoma and SMARCB1-deleted solid tumors.

CCCC Intrinsic Value
1.77 USD
Overvaluation 15%
Intrinsic Value
Price
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-395.4%
=
Operating Profit
-119.1m
/
Revenue
30.1m
What is the Operating Margin of C4 Therapeutics Inc?

Based on C4 Therapeutics Inc's most recent financial statements, the company has Operating Margin of -395.4%.

Back to Top